Organic anion transporting polypeptides (OATP) encoded by the SLCO gene family constitute clinically important transporters involved in the disposition of endogenous compounds and many commonly prescribed drugs, including statins, methotrexate and antihypertensive medications. Common genetic polymorphisms in SLCO genes are known to affect OATP function and modulate efficacy and safety of OATP substrates. However, current frequency data of these variants and haplotypes is generally based on few rather heterogenous populations of relatively small sample size. Furthermore, the genetic variability beyond these selected pharmacogenetic biomarkers has not been systematically analyzed. Here, we provide a global consolidated map of SLCO variability by leveraging fully compatible Next Generation Sequencing data from 138,632 unrelated individuals across seven major human populations. Overall, we find 9811 exonic single nucleotide variants and 155 copy number variations of which 99.3% were rare with frequencies < 1%. Using orthogonal computational functionality predictors optimized for pharmacogenetic assessments, we find that four out of five individuals carry at least one deleterious variant in an SLCO transporter gene and rare variants contribute 23% to the genetically encoded functional variability. Moreover, 74.9% of all variants were found to be population-specific with important consequences for population-specific genotyping strategies and precision public health approaches. Combined, our analyses provide the most comprehensive data set of SLCO variability published to date and incentivize the integration of comprehensive NGS-based genotyping into personalized predictions of OATP substrate disposition.
Introduction
Understanding the disposition of a drug is essential throughout pharmaceutical research, as well as in preclinical and clinical drug development. Information about drug absorption, distribution and excretion provides guidance for pharmacokinetic modeling, the prediction of potential drug-drug interactions and dose selection in early clinical trials. Drug transporter proteins are of central importance in these processes and their functional alteration can result in reduced treatment efficacy or adverse drug reactions (ADRs) [1] .
Transporters of the organic anion transporting polypeptides (OATP) family mediate cellular uptake of a variety of clinically important drugs, including various statins [2] [3] [4] , angiotensin II receptor antagonist, such as olmesartan [5] and valsartan [6] , as well as the endothelin receptor antagonist bosentan [7] and are recognized to have major impacts on the pharmacokinetic, safety and efficacy profiles. Furthermore, OATPs transport multiple endogenous substrates, such as bile acids, bilirubin, eicosanoids, prostaglandins, hormones, and their sulfated and glucuronated conjugates and are essential in maintaining bile acid and hormone homeostasis [8, 9] . In total, the human genome encodes 11 different OATP transporters of which the pharmacokinetic roles of OATP1A2, OATP1B1, OATP1B3 and OATP2B1 are most extensively characterized. OATP1B1 and OATP1B3 are expressed in the sinusoidal hepatocytes membrane with a perivenous-to-periportal expression gradient in both mice [10] and humans [11] . In contrast, OATP1A2 is predominantly expressed in the blood-brain barrier [12] and duodenal enterocytes [13] . All OATPs consist of 12 transmembrane domains with amino and carboxy termini facing the intracellular space. They mediate transport of their substrates via an elecroneutral process wherein the influx of extracellular OATP substrates is accompanied by the efflux of intracellular anions such as bicarbonate [14, 15] .
In humans OATP transporters are encoded by the SLCO gene family. Genetic variations in these genes can alter transporter activity and seminal studies have firmly established the role of selected SLCO variants in differences in pharmacokinetics and drug effects. The arguably most extensively studied example is the effect of the missense variant https://doi.org/10.1016/j.phrs.2018. 10 .017 Received 10 August 2018; Received in revised form 14 September 2018; Accepted 17 October 2018 rs4149056 in SLCO1B1 (SLCO1B1*5 and part of SLCO1B1*15) that results in elevated statin plasma concentrations due to impaired hepatic clearance [16, 17] and, in the case of simvastatin, this increased exposure has been convincingly associated with increased risks of developing myopathy [18] . Besides their pharmacogenetic relevance, mutations in SLCO genes can moreover result in congenital diseases, such as Rotor syndrome (OMIM identifier 237450) and primary hypertrophic osteoarthropathy (OMIM identifier 614441).
These and other reports have provided important frequency information of SLCO alleles with putative clinical relevance. However, these studies only analyzed heterogeneous populations of relatively small sample sizes and did not evaluate the vast repertoire of rare variants that have been identified in pharmacogenes [19] [20] [21] [22] [23] . The increasing availability of Next-Generation Sequencing (NGS) data provided by recent population-scale sequencing projects presents a paradigm shift that enables for the first time to comprehensively analyze the genetic landscape of SLCO genes beyond commonly interrogated SNPs and to map their variability across worldwide populations.
Here, we analyzed exome and whole genome sequencing (WES and WGS, respectively) data from 138,632 unrelated individuals across seven major human populations provided by the Genome Aggregation Database to provide a consolidated population-specific overview of clinically important SLCO allele frequencies on an unprecedented scale. We comprehensively portrayed the genetic diversity of the human SLCO transporter family resulting in the identification of a total of 9811 exonic variants, 3745 of which were novel. By using five partly orthogonal computational predictors and structural mapping approaches we predicted the functional importance of this genetic variability and provide estimates for their contribution to human drug response. Combined, the presented data constitutes the most comprehensive overview of genetic variability in human SLCO genes published to date and provides important guidance for the design of population-specific genotyping strategies in a precision medicine framework.
Methods

Data collection and annotation
Genetic variability data for the 11 human SLCO gene family members was collected from the Genome Aggregation Database. These data released under the Fort Lauderdale Agreement and thus, separate ethical approval was not required. The information was derived from sequencing data of 138,632 unrelated individuals from different worldwide populations (63, 369 Non-Finnish Europeans, 12,897 Finnish, 12,020 Africans, 9435 East Asians, 15,391 South Asians, 17,210 Latinos, 5076 Ashkenazi Jews and 3234 from other populations). Novel variants were defined relative to dbSNP release 135. Rare and common variants were defined as variants with minor allele frequency (MAF) < 1% and MAF ≥ 1%, respectively. Copy number variants (CNVs) data from 59,451 individuals were obtained from the Exome Aggregation Consortium and analyzed as previously described [24] . Frequencies of the wild-type (*1) alleles for SLCO genes were calculated as F WT = 1 − ∑ i F i , with F i being the frequency of each considered variant allele i.
Haplotype and linkage analyses
Haplotype definitions were obtained from PharmGKB. Haplotype frequencies were calculated by integrating population-specific variant frequencies with linkage information from the corresponding population provided by the 1000 Genomes Project using LDLink [25] .
Computational predictions
The functionality of all missense variants was analyzed using five prediction algorithms, LRT [26] , MutationAssessor [27] , PROVEAN [28] , VEST3 [29] and CADD [30] , accessed via ANNOVAR [31] , which base their assessments on a multitude of partly orthogonal features, including evolutionary conservation, functional genomic data, structural information as well as information about the genic and sequence context. The individual assessments of the algorithms were integrated using a computational predictor trained specifically for pharmacogenetic assessments [32] . In addition, variants that resulted in frameshifts, premature stop-codons, loss of start codons, inframe deletions or insertions, or disruption of splice sites were considered as putatively deleterious. CNVs that result in the deletion or duplication of one or more exons of a gene were predicted to result in nonfunctional protein products.
Structural modeling
The secondary structure of OATP1B1 was derived from domain information from UniProt (UniProt ID Q9Y6L6). SLCO1B1 exon coordinates were obtained from the GRCh37 human reference assembly. In the absence of high-resolution crystal structures of OATP1B1, we used the in silico structure prediction tool Phyre 2 [33] to build its tertiary structure.
Results
The genetic variability landscape of the human SLCO gene family
We analysed the genetic variability of all 11 genes in the human SLCO gene family using sequencing data obtained from 138,632 unrelated individuals. In total we identified 3877 intronic variants and 9811 localized to exons, 3745 of which were novel (Fig. 1A) . The majority of exonic variants resulted in amino acid changes (n = 4418), followed by variants in untranslated regions (n = 2232 and 712 in 3′ and 5′ UTRs, respectively) and synonymous variants (n = 1756; Fig. 1A ). Most exonic variants were found in SLCO5A1 (n = 1266) and SLCO1A2 (n = 1233), whereas SLCO6A1 harboured the lowest number of exonic variants (n = 595; Fig. 1B ). In contrast, when variants were normalized to gene length, SLCO4A1 (45 variants per exonic 100bp) and SLCO2A1 (37.5 variants) were genetically most diverse, whereas SLCO6A1 (7.7 variants) and SLCO1C1 (8.7 variants) were most conserved ( Supplementary Fig. 1 ). Importantly, only 239 out of the 9811 exonic variants were common with minor allele frequencies (MAF) > 1% whereas more than half of all variants (52%) were singletons (Fig. 1C) . The SLCO genes with the lowest numbers of common variants were SLCO1B1, SLCO6A1 and SLCO1C1 with 8, 8 and 12 common variants, respectively ( Supplementary Fig. 2 ). In contrast, the same genes harboured 675, 587 and 867 rare variants corresponding to > 98% of all variants in these genes. When aggregated variant frequencies are considered, rare variants were most prevalent in SLCO1A2 and SLCO5A1 with accumulated MAFs of rare variants of 26.7% and 23.1%, respectively, whereas SLCO6A1 and SLCO1C1 harboured the lowest frequencies of rare variants (MAF = 6.6% and 6.8%, respectively).
Worldwide frequencies of functionally relevant variants in human SLCO genes
Genetic variations in SLCO genes have been consistently linked to changes in drug response. We thus analysed the frequencies of 37 human SLCO alleles with putative functional relevance in major human populations (Table 1 ). In SLCO1A2 we analyzed eight SNVs and found that their frequencies were highly population-specific. SLCO1A2*2 and the decreased functionality allele SLCO1A2*3 [34] were most prevalent in Ashkenazim (MAF *2 = 14.5% and MAF *3 = 3.4%) and European populations (MAF *2 = 13.6% and MAF *3 = 6.2%) but absent in East Asians (MAF < 0.1%). In contrast, SLCO1A2*5 and SLCO1A2*7, which are implicated in reduced uptake of the δ-opioid receptor agonist deltorphin II [34] , are found exclusively in African populations with MAF of 2% and 4.7%, respectively. The variant rs141690450 that causes reduced methotrexate uptake in vitro [35] was specific for Ashkenazim (MAF = 0.5%), whereas SLCO1A2*4 and SLCO1A2*6 were very rare or not identified in any population analyzed.
Genetic variability in SLCO1B1 has been associated with altered pharmacokinetics of various statins (atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin), meglitinides (nateglinide and repaglinide), thiazolidinediones (pioglitazone and rosiglitazone), fexofenadine, methotrexate and various others [36] . SLCO1B1*1B constitutes the most common variant allele with frequencies between 9.7% in Ashkenazim and 62% in East Asians. The functional impact of the *1B allele has been reported to be substratespecific as transport appears to be increased for bromosulfophthalein [37] and rosuvastatin [38] , unchanged for estradiol-17β-glucuronide [37, 39, 40] , pravastatin [41] , and atrasentan [42] , but decreased for rifampicin [43] , ezetimibe [44] and cholyltaurine [37] . The predominant decreased functionality allele in all populations was SLCO1B1*15, defined by rs4149056 and rs2306283, with frequencies between 2.9% in Africans and 15.4% in Ashkenazi Jews. In contrast, SLCO1B1*5 (rs4149056 without the rs2306283 variant) was only detected in Europeans (MAF = 2.8%), Latinos (MAF = 1.7%) and Ashkenazim (MAF = 2.5%). Furthermore, SLCO1B1 harbored a multitude of population-specific variants, including rs59502379 (SLCO1B1*9), rs59113707 (part of the SLCO1B1*27 haplotype) and rs74064213 in Africans, rs201722521 in South Asians and rs61760182 and rs61760243 in Ashkenazi Jews.
In addition, two common variants in SLCO1B3, rs4149117 (S112A) and rs7311358 (M233I), were analysed and were found to be in complete linkage disequilibrium in all populations analyzed in contrast to previous reports [45] . The corresponding haplotype occurred with frequencies between 42.6% in Africans and 90.5% in South Asians. In heterologous expression systems, OATP1B3 S112A;M233I exhibited reduced transport of cholecystokinin octapeptide and rosuvastatin, whereas atorvastatin uptake was not affected [46] . Similar substratespecific effects have been reported in vivo where the variant haplotype correlated with decreased mycophenolic acid [47] and docetaxel [48] disposition whereas no effects were observed for clearance of the OATP1B3 substrate paclitaxel [45] . Among the three SLCO2B1 variants that we analyzed, rs2306168 (SLCO2B1*3) and rs12422149 were common in each population analyzed, whereas rs1621378 (SLCO2B1*2) was only detected in two out of 9435 East Asian individuals. SLCO2B1*2 has been reported to be functionally neutral [49] . In contrast, the SLCO2B1*3 allele associates with altered pharmacokinetics of fexofenadine [50] and celiprolol at therapeutic doses but not at microdoses [51, 52] . However, no effect of SLCO2B1*3 on montekulast clearance was observed, whereas the common SLCO2B1 variant rs12422149 significantly associated with montelukast pharmacokinetics and response [53] . Notably, SLCO1A2, SLCO1B1, SLCO1B3 and SLCO1C1 reside in close proximity in a cluster on chromosome 12 and variants within these genes are in strong linkage disequilibrium (LD; Supplementary Fig. 1 . C, Of all exonic SLCO variants, 99.3 and 98% were rare or very rare with global minor allele frequencies < 1% and < 0.1%, respectively. Furthermore, 52.2% were singletons found only in one single allele.
(S112A and M233I in SLCO1B3), which are themselves completely linked. In contrast, these variants are not considerably linked in Africans, Latinos and South Asians with R 2 < 0.05.
Rare genetic variants in SLCO genes are predicted to substantially contribute to variability in transporter function
Next, we comprehensively profiled the putative functional consequences of human SLCO variability including rare variants. To this end, we considered all variants that affected the amino acid sequence of the corresponding gene product (n = 5092). These constituted of 4418 missense variants as well as 674 frameshift, stop gain, start lost, inframe deletions and insertions, and splice site variants (Fig. 3A) . First, we predicted the functional consequences of all missense variants using an ADME optimized prediction framework (see methods section). We could obtain predictions for 4308 of the 4418 identified missense variants (97.5%), 1281 of which were classified as putatively deleterious. These variants were complemented with all detected frameshift, stop gain, start lost, inframe deletions and insertions, as well as splice site variants, resulting in a total of 1955 putatively deleterious variants. Notably, most rare variants with functional effects were detected in SLCO1B3 (n = 252) and SLCO1B1 (n = 237), whereas SLCO3A1 harboured substantially less deleterious variants (n = 69). Of the 35 common variants only 4 (11.4%) were predicted to have functional consequences, the missense variants rs4149056 in SLCO1B1, rs60140950 in SLCO1B3, rs11568563 in SLCO1A2 and the 9bp inframe deletion rs778264542 in SLCO2B1. In contrast, deleterious variants were much more prevalent among the rare variants, constituting 39% (n = 1951) of the 5056 variants (Fig. 3B) .
In addition to SNVs and indels, we found a total of 155 copy number variations (CNVs) distributed across 10 out of the 11 human SLCO genes (Fig. 3C) . Most CNVs were detected in SLCO1B3 (n = 58), whereas SLCO1A2, SLCO1C1, SLCO2A1, SLCO2B1, SLCO4A1 and SLCO5A1 all harboured less than 10 CNVs. The majority of CNVs in most genes were deletions, whereas duplications were more common in SLCO6A1 (11 duplications and 8 deletions) . Notably, all identified CNVs in SLCO genes were very rare with global frequencies < 0.1%.
To identify the overall relevance of SLCO variations, we integrated SNV and CNV variability data and found that the functional mutational burden differed substantially across SLCO genes (Fig. 3D) . While every Fig. 3 ). When both common and rare variants were considered, we found that deleterious variations across the entire human SLCO gene family occurred with an aggregated frequency of 0.82 variants per individual, implying that four out of five individuals carry at least one deleterious variant in an SLCO transporter gene.
Genetic variability in SLCO genes is highly population-specific and results in distinct functionality profiles
Importantly, by comparing genetic variability across seven major populations, including Europeans, Africans, East Asians, South Asians, Latinos, Finnish and Ashkenazi Jews, we found that the vast majority of coding variants within human SLCO genes were population-specific. The fraction of population-specific variants was highest in SLCO1C1 and SLCO4C1 (85.6% and 84.3% of all variants, respectively) and lowest in SLCO4A1 (65.7%; Fig. 4A ). In contrast, only 0.2-1.4% of variants were shared between all populations analysed. Strikingly, 3813 out 5092 variants (74.9%) were found to be specific for one of the seven Fig. 2 . Linkage disequilibrium and haplotype type structure of the SLCO cluster on chromosome 12. Linkage disequilibrium map of 14 common single nucleotide polymorphisms in the SLCO1C1, SLCO1B3, SLCO1B1 and SLCO1A2 locus. Colour code indicates normalized linkage disequilibrium coefficient (D'). Note that two haplotype blocks were identified (indicated with black frames). Fig. 3 . Rare genetic variants contribute substantially to the overall genetic variability in human SLCO genes. A, In total 5092 variants were identified that affected the amino acid sequence of the corresponding gene product. Of these 674 were allotted to frameshift, stop gain, start lost, small indels and splice site variants and were subsequently considered as putatively deleterious. Of all 4418 missense variants, 1281 were predicted to be deleterious, whereas 3027 were putatively neutral and no prediction could be obtained for 110 variants. Of the resulting 1955 putatively deleterious variants only 4 were common and 1951 were rare with MAF ≥ 1% and < 1%, respectively. Inlet column plot depicts the distribution of these 1951 rare deleterious variants across SLCO genes. B, Only 4 out of 35 common SLCO variants were putatively deleterious (11.4%). In contrast, 1951 of 5056 (38.6%) of all rare variants that affected the amino acid sequence of the respective gene product were classified as putatively deleterious. C, In addition to single nucleotide variants (SNVs) and indels we detected a total of 335 copy number variations (CNVs) distributed across 10 out of 11 human SLCO genes. D, Stacked column plot showing the number of deleterious variants per (diploid) individual. Combined, deleterious variations in the SLCO gene family occurred with an aggregated frequency of 0.82 variants per individual of which 23% were allotted to rare variants.
analysed populations whereas only 1279 variants were found in more than one population (Fig. 4B) . The highest number of population-specific variants was observed in SLCO1B3 (n = 446) and SLCO5A1 (n = 410), while fewest were found in SLCO2A1 (n = 271; Fig. 4C ).
When only putatively deleterious variants were considered, individuals harboured most variants in SLCO1B3 (0.28 variants per individual) whereas SLCO3A1 was 100 times less variable (0.002 variants per individual; Fig. 4D ). The widest range of genetic variability across populations was observed in SLCO1B3 (0.04 to 0.43 variants per individual in East Asians and Ashkenazim, respectively) and SLCO1B1 (0.21 to 0.43 variants per individual in South Asians and Finns, respectively), whereas in SLCO3A1, SLCO4A1, SLCO4C1, SLCO5A1 and SLCO6A1 individuals harboured < 0.05 variants across all populations. Interestingly, while the overall genetic variability in SLCO genes was remarkably similar across populations, there were pronounced differences in the number of deleterious variants between populations (compare Fig. 4E and Supplementary Fig. 4 ).
Structural map of SLCO1B1 variability
Since our analyses showed that most variants in SLCO genes with putatively deleterious consequences were missense variants, we mapped the genetic variability onto the respective OATP protein domain structure. As no crystal structures of OATP transporters have yet been resolved, we used for this approach the most extensively studied and clinically most relevant transporter for which three-dimensional structure-activity relationship models are available [54] . We modeled OATP1B1 using Phyre 2 , a computational tool that derives structural predictions based on multiple sequence alignments and currently available experimental models [33] . OATP1B1 variability was not evenly distributed across its domain structure (Fig. 5A) . The common missense variants N130D and P155 T were found in EC2, whereas V174A and L643F localized to the transmembrane domains TM4 and TM12, respectively (Fig. 5A) . Frequencies of these common variants differed substantially across populations. Most drastic differences were found for P155T that differed between < 0.1% in East Asians and 19.8% in Ashkenazi Jews. Similarly, V174A reached frequencies of 17.9% in Ashkenazim but only 2.9% in African populations. In addition, we found five variants that occurred with a frequency above 0.1%; I211M, I245V and P400L were found in IC3, EC3 and IC5, respectively, whereas G488V and I499V localized to the large extracellular domain EC5. Overall, 510 variants affecting OATP1B1 amino acid sequence were localized to 360 different residues. Most variants were found in the large fifth extracellular domain (EC5) and in the fourth transmembrane domain (Fig. 5B) . However, when variant numbers were normalized to domain size, most variants were found in the transmembrane domains TM4 and TM7 and the third extracellular domain EC3, whereas IC5, TM8 and IC6 where most highly conserved (Fig. 5C ). Of note, variations in the asparagine residues N134, N503 and N516 whose glycosylation was shown to be important for transport function [55] were very rare with frequencies < 0.01%. In total, 238 of the 510 variants were predicted to be putatively deleterious and these variants were distributed across a total of 171 different residues. Deleterious variants mapped primarily to extracellular and transmembrane domains, whereas few variants in the intracellular domains were predicted to result in functional consequences (Fig. 5D) . Combined, these data highlight the substantial complexity of the mutational spectrum of OATP1B1.
Discussion
Multiple OATP transporters encoded by the SLCO gene family are factors of paramount importance for drug pharmacokinetics. Specifically multiple genetic polymorphisms in SLCO1B1, SLCO1B3, SLCO1A2 and SLCO2B1 have been mechanistically implicated in altered drug response and toxicity. Thus, understanding of the genetic SLCO variability constitutes a potentially important area for the personalization of pharmacological treatment. However, reports published to date analysed only the frequencies of a low number of candidate SNPs in individual subpopulations of relatively small sample size [49, [56] [57] [58] [59] [60] [61] .
Importantly, the rapid technological progress and increased dissemination of NGS has allowed a paradigm shift away from candidate variant studies towards comprehensive analyses of genomic variability. Here, we leveraged fully consistent and compatible genomic information of 138,632 unrelated individuals across seven worldwide human populations to systematically map the genomic landscape of the human SLCO transporter gene family. The resulting data provide the most comprehensive overview of functionally relevant SLCO alleles published to date with important implications for population-specific differences in drug disposition.
Our analyses revealed substantial interethnic differences in the frequencies of functionally important SLCO alleles. Specifically, we found that the potentially hyperactive SLCO1A2*2 allele as well as the decreased functionality *3 allele of SLCO1A2 were most common in Europeans and Ashkenazim, whereas they were absent in East Asians. These results might have clinically relevant implications for treatment with SLCO1A2 (OATP1A2) substrates, such as methotrexate, various statins and bile acid-cisplatin conjugates [62, 63] . Similarly, frequencies of the important SLCO1B1 alleles *1B, *5, *9, *14 and *15 differed considerably between the analysed populations with important consequences particularly for statin therapy. Importantly, pharmacokinetics of various statins differ substantially across ethnicities with East Asians having the highest exposure levels, while levels in Caucasians and Africans were substantially lower [64] [65] [66] . Interestingly, while the V174A and N130D variants explained part of the inter-individual variability within ethnic groups, statin exposure remained significantly different between ethnicities even after correcting for common SLCO1B1 genotypes, indicating that other genetic or non-genetic factors are also contributing [64] [65] [66] . Notably, a recent exome sequencing study in various African populations reported a variety of populationspecific SLCO1B1 variants, explaining inter-individual differences in statin pharmacokinetic [67] . Overall, the extent of interethnic variability of SLCO alleles was found to be similar to other highly variable pharmacogene families, such as CYPs [68] and UGTs [69] . As a result, these data pinpoint variants of highest priority in a population of interest and incentivize the design of population-adjusted genotyping strategies to optimize precision public health initiatives.
Previously described alleles accounted only for a small fraction of the genetic variability in the human SLCO gene family and more than 99% of all identified variants were found to occur with MAF < 1%. Importantly, our computational analyses indicate that the contribution of rare variants to the genetically encoded functional variability of OATP transporters is considerable and highly gene-dependent. For 7 out of the 11 human SLCO genes rare variants were the sole source of genetically encoded functional variability, whereas they accounted for 9.1%-13.7% for SLCO1B1, SLCO2B1 and SLCO1A2. However, translation of a patient's rare genetic variant information in a clinical setting remains challenging as current computational prediction methods are developed for the analysis of disease-associated variability that is characterized by substantial evolutionary constraints, resulting in a relatively low predictive power when used for pharmacogenomic assessments [70] . In the present study we therefore used a prediction framework specifically designed for and trained on pharmacogenomic data sets [31] . While this strategy promises to improve the accuracy of computational predictions, evaluation of the added value of such NGSguided care with regards to patient benefits and cost-effectiveness has not been evaluated in a prospective trial and remains one of the most important frontiers in the personalization of treatment decisions [71, 72] .
In conclusion, we systematically mapped the genetic landscape of the human SLCO transporter family on an unprecedented scale. These analyses reveal that variability at SLCO loci is highly complex with vast numbers of rare and population-specific variants. Computational analyses based on orthogonal evolutionary, structural and functional genomics data indicate that rare variants contribute considerably to the genetically encoded functional variability in OATP transporters. Thus, these data incentivize the integration of comprehensive NGS-based genotyping into personalized predictions of OATP substrate disposition.
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